of persons in this age group to antigenically related influenza viruses earlier in life, resulting in the development of cross-protective antibodies ( Table 2 in the Supplementary Appendix). 10, 14 Rates of illness from 2009 H1N1 virus infection have varied, but during one outbreak in New Zealand, the attack rate of illness was estimated at 7.5%, and the attack rate of overall infection was estimated at 11%. 15 An estimated one third of infections in one boarding school were subclinical. 16 After the peak of a second wave of infection in Pittsburgh, the seroprevalence of hemagglutination-inhibition antibody suggested that about 21% of all persons and 45% of those between the ages of 10 and 19 years had become infected. 17 The overall case fatality rate has been less than 0.5%, and the wide range of estimates (0.0004 to 1.47%) reflects uncertainty regarding case ascertainment and the number of infections. [18] [19] [20] The case fatality rate for symptomatic illness was estimated to be 0.048% in the United States 21 and 0.026% in the United Kingdom. 13 In contrast to seasonal influenza, most of the serious illnesses caused by the pandemic virus have occurred among children and nonelderly adults, and approximately 90% of deaths have occurred in those under 65 years of age.
Rates of hospitalization and death have varied widely according to country. 22 Hospitalization rates have been highest for children under the age of 5 years, 22 especially those under the age of 1 year, and lowest for persons 65 years of age or older. 23 In the United States, among patients who were hospitalized with pandemic influenza, 32 to 45% were under the age of 18 years. 23, 24 Approximately 9 to 31% of hospitalized patients have been admitted to an intensive care unit (ICU), where 14 to 46% of patients have died. [23] [24] [25] [26] [27] The overall case fatality rate among hospitalized patients appears to have been highest among those 50 years of age or older and lowest among children. 1, 13, 23, 27 
Transmission and Outbreaks
The mechanisms of person-to-person transmission of the 2009 H1N1 virus appear to be similar to those of seasonal influenza, but the relative contributions of small-particle aerosols, large droplets, and fomites are uncertain. Rates of secondary outbreaks of illness vary according to the setting and the exposed population, but estimates range from 4 to 28%. Household transmission is highest among children and lowest among adults over 50 years of age. 28, 29 In the United Kingdom and the United States, the rates of secondary outbreaks in households were 7% and 13%, respectively, with children at increased risk for infection by a factor of two to four. 16, 28 Many outbreaks have occurred in schools, day-care facilities, camps, and hospitals. 16, 30, 31 Estimates of the basic reproduction number (the mean number of secondary cases of infection transmitted by a single primary case in a susceptible population) generally range from 1.3 to 1.7 according to the setting, which are similar to or slightly higher than the estimates for seasonal influenza, 20,32,33 but may be as high as 3.0 to 3.6 in outbreaks in crowded schools. 31 
Risk Groups and Risk Factors for Severe Disease
Approximately one quarter to one half of patients with 2009 H1N1 virus infection who were hospitalized or died had no reported coexisting medical conditions. 13, 23, 26, 27, 34 Underlying conditions that are associated with complications from seasonal influenza also are risk factors for complications from 2009 H1N1 virus infection (Table 1) . Pregnant women (especially those in the second or third trimester), women who are less than 2 weeks post partum, and patients with immunosuppression or neurologic disorders have also been overrepresented among those with severe 2009 H1N1 virus infection. 23, 24, 26, 35 Although pregnant women represent only 1 to 2% of the population, among patients with 2009 H1N1 virus infection, they have accounted for up to 7 to 10% of hospitalized patients, 22-24 6 to 9% of ICU patients, 26,27 and 6 to 10% of patients who died. 23, 35 There appears to be a particularly increased risk of death among infected women during the third trimester, 36 especially among those who have coinfection with the human immunodeficiency virus (HIV). 37 Among patients with severe or fatal cases of 2009 H1N1 virus infection, severe obesity (bodymass index [the weight in kilograms divided by the square of the height in meters], ≥35) or morbid obesity (body-mass index, ≥40) has been reported at rates that are higher by a factor of 5 to 15 than the rate in the general population. 23, 26, 27, 38 In addition to obesity-associated risks, such as cardiovascular disease and diabetes, possible adverse immunologic effects and management problems related to obesity may be contributory.
In certain disadvantaged groups, including indigenous populations of North America and the Australasia-Pacific region, rates of severe 2009 H1N1 virus infection have been increased by a factor of five to seven. 23, 26, 27 Factors that may contribute to this trend include crowding; an increased prevalence of underlying medical disorders, alcoholism, and smoking 27 ; delayed seeking of or access to care; and possibly unidentified genetic factors. Aboriginal status, the presence of coexisting conditions, and delayed receipt of antiviral therapy were independently associated with severe disease in one Canadian study. 39 
Pathogenesis

Viral Replication
Studies of hemagglutinin-receptor binding indicate that the 2009 H1N1 virus is well adapted to mammalian hosts and binds to both α2,6-linked cellular receptors (as do seasonal influenza viruses) and α2,3-linked receptors, 40 which are present in the conjunctivae, distal airways, and alveolar pneumocytes. The 2009 H1N1 virus shows increased ex vivo replication in human bronchial epithelium at 33°C, as compared with a seasonal influenza virus, 41 and is also characterized by increased replication and pathological changes in the lungs of nonhuman primates and increased replication in ex vivo human lung tissues. 10 Such observations may help explain the ability of the virus to cause severe viral pneumonitis in humans.
In uncomplicated illness, nasopharyngeal viral RNA loads peak on the day of onset of symptoms and decline gradually afterward. 42 However, viral replication may be more prolonged than in seasonal influenza, and on day 8 of uncomplicated illness in adults and teenagers, nasopharyngeal swabs have yielded viral RNA in 74% of patients and infectious virus in 13% of patients. 30, 43 Infectious virus has been recovered from children up to 6 days after the resolution of fever.
Nasopharyngeal viral loads are increased in patients with severe pneumonia and decline slowly in critically ill patients. 44 Among intubated patients, viral RNA has been detected at higher levels and for longer periods in the lower respiratory tract than in the upper respiratory tract. 45 Viral RNA may be detected in secretions from the lower respiratory tract up to 28 days after the onset of 47 As compared with patients with less severe illness, patients who died or who had the acute respiratory distress syndrome (ARDS) had increased plasma levels of interleukin-6, interleukin-10, and interleukin-15 throughout the illness and of granulocyte colony-stimulating factor, interleukin-1α, interleukin-8, interferon-inducible protein 10, and tumor necrosis factor α during the late phase of illness. 44 Levels of serum hemagglutination-inhibition and neutralizing antibodies rise promptly after infection in immunocompetent persons, 14 but symptomatic reinfections have been reported. 49
Pathological Features
In fatal cases of H1N1 virus infection, the most consistent histopathological findings are varying degrees of diffuse alveolar damage with hyaline membranes and septal edema, tracheitis, and necrotizing bronchiolitis [50] [51] [52] (Fig. 1 ). Other early changes include pulmonary vascular congestion and, in some cases, alveolar hemorrhage. In addition to infecting cells in upper respiratory and tracheobronchial epithelium and mucosal glands, the 2009 H1N1 virus targets alveolar lining cells (type I and II pneumocytes) 50 (Fig. 2 ). Viral antigens have been readily detectable in about two thirds of patients who died within 10 days after the onset of illness and may be detectable for more than 10 days. 50 Other autopsy findings include hemophagocytosis, pulmonary thromboemboli and hemorrhage, and myocarditis. 44 Bronchopneumonia with evidence of bacterial coinfection has been found in 26 to 38% of fatal cases. [50] [51] [52] Clinic a l Fe at ur es
Incubation Period
The incubation period appears to be approximately 1.5 to 3 days, which is similar to that of seasonal influenza. 18, 28, 31, 32, 53 In a minority of patients, the period may extend to 7 days.
Clinical Presentation
Infection with the 2009 H1N1 virus causes a broad spectrum of clinical syndromes, ranging from afebrile upper respiratory illness to fulminant viral pneumonia. Mild illness without fever has been reported in 8 to 32% of infected persons. 53 Most patients presenting for care have typical influenzalike illness with fever and cough, symptoms that are sometimes accompanied by sore throat and rhinorrhea (Table 2) . 2,24,34,53-56 Systemic symptoms are frequent. Gastrointestinal symptoms (including nausea, vomiting, and diarrhea) occur more commonly than in seasonal influenza, especially in adults. 3, 57 Dyspnea, tachypnea in children, chest pain, hemoptysis or purulent sputum, prolonged or recurrent fever, altered mental status, manifestations of dehydration, and reappearance of lower respiratory tract symptoms after improvement are signs of progression to more severe disease or complications. 2, [25] [26] [27] 58 The principal clinical syndrome leading to hospitalization and intensive care is diffuse viral pneumonitis associated with severe hypoxemia, ARDS, and sometimes shock and renal failure. 26, 27 This syndrome has accounted for approximately 49 to 72% of ICU admissions for 2009 H1N1 virus infection. 26, 27 Rapid progression is common, typically starting on day 4 to 5 after the onset of illness, and intubation is often necessary within 24 hours after admission. Currently available prognostic algorithms for community-acquired pneumonia, such as CURB-65 (a measure of confusion, urea nitrogen, respiratory rate, and blood pressure and an age of 65 years or older), may not apply. 58 Radiographic findings commonly include diffuse mixed interstitial and alveolar infiltrates, although lobar and multilobar distributions occur, particularly in patients with bacterial coinfection. Chest computed tomography has shown multiple areas of ground-glass opacities, air bronchograms, and alveolar consolidation, particularly in the lower lobes. 24 Small pleural effusions occur, but an increased volume suggests volume overload or possibly empyema. Pulmonary thromboemboli have occurred in some critically ill patients with ARDS. Other important syndromes include severe, prolonged exacerbation of chronic obstructive pulmonary disease (COPD) or asthma (in about 14 to 15% of patients), bacterial coinfections, and decompensation of serious coexisting conditions (Table  1) . 23, 26, 27 Among hospitalized patients with 2009 H1N1 infection, a history of asthma has been reported in 24 to 50% of children and adults, and COPD in 36% of adults. 23, 24 Bacterial pneumonia, usually caused by Staphylococcus aureus (often methicillin-resistant), Streptococcus pneumoniae, S. pyogenes, and sometimes other bacteria, has been suspected or diagnosed in 20 to 24% of ICU patients and has been found in 26 to 38% of patients who died, often in association with a short clinical course. 26, 27, 50, 52 Death from 2009 H1N1 virus and bacterial coinfection has occurred within 2 to 3 days in some cases. Sporadic cases of neurologic manifestations (confusion, seizures, unconsciousness, acute or postinfectious encephalopathy, quadriparesis, and encephalitis) 59 and myocarditis have been reported, including some fulminant cases.
Laboratory findings at presentation in patients with severe disease typically include normal or low-normal leukocyte counts with lymphocytopenia and elevations in levels of serum aminotransferases, lactate dehydrogenase, creatine kinase, and creatinine. 2, 25, 27 Myositis and rhabdomyolysis have occurred in severe cases. A poor prognosis is associated with increased levels of creatine kinase, creatinine, and perhaps lactate dehydrogenase, as well as with the presence of thrombocytopenia and metabolic acidosis ( 2716 (43) 218 (85) 206 (95) 115 (94) 143 (95) 18 (100) 153 (36) 181 (89) 52 (81) Myalgias 1900 (30) 80 (31) 41 (19) 22 (18) 76 (51) 8 (44) 43 (10) 6 (3) 20 ‡ Cough 2550 (40) 220 (86) 128 (59) 100 (82) 139 (93) 18 (100) 296 (70) 141 (69) 49 (73) Headache 2480 (39) 75 (29) 28 (13) 24 (20) 68 (45) 4 (22) 83 ( 63 (25) 72 (33) 55 (45) 48 (32) 5 (28) 101 (24) 63 (31) 45 ( 22 (9) 13 (6) 28 (23) 38 (25) 4 (22) 12 (3) 17 ( virus has been reported, 62 and respiratory transmission from a symptomatic mother to a newborn can occur during the postpartum period. Newborn infants may also have apnea, tachypnea, cyanosis, and lethargy. Pregnant women are at increased risk for severe illness, spontaneous abortion, preterm labor and birth, and fetal distress. 35, 36, 57 Afebrile or atypical presentations have occurred in pregnant women, patients with immunosuppression, those undergoing hemodialysis, and other risk groups (Table 1) . Patients with severe immunosuppression are at increased risk for protracted viral replication and pneumonia. 63, 64 Di agnosis
Clinical Factors
Clinical suspicion and the accuracy of diagnosis vary substantially, depending on whether the case occurs sporadically or during a recognized outbreak, when a typical presentation of influenzalike illness is likely to represent 2009 H1N1 virus infection. However, the wide clinical spectrum of 2009 H1N1 virus infection and its features that overlap with those of other common infections have sometimes led to the misdiagnosis of other potentially treatable infections (e.g., legionellosis, meningococcemia, leptospirosis, dengue, and malaria). 58 Coinfection with dengue or certain respiratory viruses (parainfluenza virus and respiratory syncytial virus) and detection of S. pneumoniae have been reported in some patients with severe 2009 H1N1 virus infection. 65 Coinfection with other respiratory viruses, including seasonal influenza virus, has also been reported. 34, 65 Virologic Factors Viral RNA detection by conventional or real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay remains the best method for the initial diagnosis of 2009 H1N1 virus infection. 58 Nasopharyngeal aspirates or swabs taken early after the onset of symptoms are suitable samples, but endotracheal or bronchoscopic aspirates have higher yields in patients with lower respiratory tract illness. 46 The 2009 H1N1 virus replicates in various cell types, 67 but isolation usually takes several days. Serologic assays (microneutralization and hemagglutination inhibition) that detect increases in antibody levels in paired serum samples provide a retrospective diagnosis; single high titers in serum samples from convalescent patients may be indicative of recent infection, 14 but routine testing of a single specimen to detect recent infection is not recommended.
Clinic a l M a nagement
Antiviral Therapy
The currently circulating 2009 H1N1 virus is susceptible to the neuraminidase inhibitors oseltam ivir (Tamiflu) and zanamivir (Relenza) but is almost always resistant to amantadine and rimantadine. 3, 10 Therapy with a neuraminidase inhibitor is especially important for patients with underlying risk factors, including pregnancy, 68 and those with severe or progressive clinical illness (Table 3) . 69 Standard doses of oseltamivir or inhaled zanamivir can be used for the treatment of mild illness, unless viral resistance to oseltamivir has been documented or is suspected (e.g., because of chemoprophylaxis failure), in which case zanamivir is preferred.
Early therapy with oseltamivir in patients with 2009 H1N1 virus infection may reduce the duration of hospitalization 70 and the risk of progression to severe disease requiring ICU admission or resulting in death. 24, 35, 36 In one study involving 45 patients with 2009 H1N1 virus who had cancer or had undergone hematopoietic stem-cell transplantation, 18% had pneumonia and 37% were hospitalized; all patients received oseltamivir, and no deaths were reported. 
Comments
Patients at increased risk for severe or complicated illness Start treatment with oseltamivir or inhaled zanamivir as soon as possible after the onset of illness if patient presents with uncomplicated illness. Do not delay treatment pending laboratory diagnosis.
Patients with severe or progressive disease and hospitalized patients Consider the use of an increased dose of oseltamivir (e.g., 150 mg twice daily) and an increased duration of treatment (e.g., 10 days). The use of intravenous peramivir or zanamivir (if available) provides reliable drug delivery, especially in critically ill patients. Do not delay treatment pending laboratory diagnosis or stop treatment if initial test results are negative in suspected cases; treatment is warranted, even when delayed, whenever active viral replication is likely. Systemic corticosteroids are not recommended for routine treatment of lung injury.
Otherwise healthy patients with uncomplicated illness Consider the use of oseltamivir or zanamivir, depending on clinical judgment and antiviral supply. Treatment is reasonable in patients presenting early (<48 hr) after the onset of febrile respiratory illness.
Instruct all patients to return for follow-up if signs or symptoms of progressive disease develop or if there is no improvement within 72 hours after symptom onset.
Neonates and young infants Start weight-based oseltamivir (3.0 mg/kg/dose) once daily from birth to 13 days of age and twice daily from 14 days to 12 mo of age.
If an oral pediatric formulation of oseltamivir is not available, prepare a modified dose from hard capsules (www.tamiflu .com/hcp/dosing/extprep.aspx).
Pregnant women Start oseltamivir or zanamivir as soon as possible after illness onset. If antipyretic drugs are considered necessary, use acetaminophen (paracetamol); avoid the use of nonsteroidal antiinflammatory drugs, including aspirin, which have been associated with fetal risks and maternal bleeding.
Breast-feeding women Start oseltamivir or zanamivir; breast-feeding can be continued. Take appropriate infection-control precautions. Oseltamivir has been found in breast milk in laboratory animals.
Patients with immunosuppression
If oseltamivir is administered, consider an uninterrupted regimen of 10 days; inhaled zanamivir is an option for uncomplicated disease.
Monitor patients for the clearance of virus. If there is evidence of protracted replication, consider possible emergence of oseltamivir resistance.
Patients with suspected or proven oseltamivir-resistant virus Start inhaled zanamivir in patients with uncomplicated illness; intravenous zanamivir (if available) should be used in patients with severe or progressive clinical illness. The risk of oseltamivir resistance is increased among patients with prolonged illness, particularly those with severe immunosuppression receiving oseltamivir for an extended duration, and those in whom chemoprophylaxis has failed. In uncomplicated illness, the early use of oseltamivir is usually associated with prompt clearance of infectious 2009 H1N1 virus from the upper respiratory tract. 53 However, infectious virus has commonly been detected after the resolution of fever and has sometimes been detected after the completion of therapy, 30 and viral RNA of uncertain clinical significance may be detectable for up to 12 days after the onset of illness. 74 In one study, the independent risk factors for prolonged viral RNA detection were an age of less than 14 years, male sex, and an interval of more than 48 hours between the onset of illness and the start of oseltamivir treatment. 53 In severely ill patients, viral RNA may be detectable in endotracheal aspirates for several weeks after the initiation of oseltamivir therapy. 45, 46 An increased dose of the drug (e.g., 150 mg twice daily in adults) and particularly an increased duration of therapy (e.g., a total of 10 days) with avoidance of treatment interruptions are reasonable in patients with pneumonia or evidence of clinical progression. 69 Doses of up to 450 mg twice daily have been administered successfully in healthy adults, and controlled studies of higherdose regimens are in progress. Higher weightadjusted doses are also required in infants and young children to provide drug exposure similar to that in adults. 69,75 Bioavailability in critically ill patients receiving oseltamivir by nasogastric tube appears to be similar to that in patients with uncomplicated illness. 76 The tolerability and efficacy of inhaled zanamivir have not been adequately studied in patients with severe influenza. However, the failure of inhaled zanamivir therapy to clear virus in patients with pneumonia has been reported. 63 Some seriously ill patients treated with inhaled zanamivir have had respiratory distress, and nebulized delivery of extemporaneously prepared solutions of zanamivir powder with its lactose carrier has been associated with lethal ventilator dysfunction. 77 
Oseltamivir Resistance
A His275Tyr mutation in viral neuraminidase confers high-level resistance to oseltamivir but not to zanamivir. 3, 78 Most oseltamivir-resistant 2009 H1N1 viruses have been sporadic isolates from treated patients, particularly those with immunosuppression who received prolonged oseltamivir therapy 63, 64 or those in whom postexposure oseltamivir chemoprophylaxis failed. 78 However, oseltamivir-resistant isolates have been found in patients without known exposure to oseltamivir and in limited clusters of cases associated with person-to-person transmission in otherwise healthy patients and those with immunosuppression. 78, 79 Although in most cases oseltamivir-resistant variants have caused mild, self-limited illness, they have been associated with pneumonia in children and with severe, sometimes fatal illness in patients with immunosuppression. 64, 78, 80 
Intravenous Neuraminidase Inhibitors
Intravenous administration of zanamivir or pera mivir provides rapid drug delivery at high levels ( Table 5 in the Supplementary Appendix). The efficacy of intravenous peramivir appeared to be similar to that of oseltamivir in one study of adults hospitalized with seasonal influenza, 81 but peram ivir is less active by a factor of at least 80 for oseltamivir-resistant viruses carrying the His275Tyr mutation than for oseltamivir-susceptible viruses. Major gaps exist in our understanding of viral transmission, pathogenesis of disease, genetic and other host factors related to susceptibility 84,85 or disease severity, and optimal management of severe illness. The development of new antiviral regimens with improved effectiveness, combinations with targeted adjunctive therapies (i.e., immunodulators and neutralizing antibodies or immunotherapy), and improved management of influenza-associated ARDS are priorities, along with better prevention, recognition, and treatment of invasive bacterial coinfections. Available findings highlight the importance of early use of antiviral drugs and antibiotics in the treatment of serious cases and of the potential value of influenza-specific and pneumococcal vaccines for prevention. Both the gaps in knowledge and the experience to date underline the urgent need for better international collaboration in clinical research, particularly in the case of diseases with pandemic potential, for which rapid detection, investigation, and characterization of clinical syndromes are prerequisites for improved mitigation of their public health consequences.
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